CALGARY, ALBERTA--(MARKET WIRE)--Sep 10, 2007 -- Resverlogix Corp. ("Resverlogix") (Toronto:RVX.TO - News) is pleased to announce positive results from preliminary proof-of-concept studies for Resverlogix's TGF-Beta Shield (TM) as a potential new therapy for the treatment of glaucoma.
